These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33414026)

  • 1. The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
    Goldsberry WN; Summerlin SS; Guyton A; Caddell B; Huh WK; Kim KH; Liang MI
    Gynecol Oncol; 2021 Mar; 160(3):800-804. PubMed ID: 33414026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Liang MI; Chen L; Hershman DL; Hillyer GC; Huh WK; Guyton A; Wright JD
    Gynecol Oncol; 2021 Mar; 160(3):793-799. PubMed ID: 33375989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
    Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.
    Zullig LL; Wolf S; Vlastelica L; Shankaran V; Zafar SY
    J Manag Care Spec Pharm; 2017 Apr; 23(4):407-411. PubMed ID: 28345445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
    Farano JL; Kandah HM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
    Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV
    JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
    Brouwer E; Yeung K; Barthold D; Hansen R
    J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
    [No Abstract]   [Full Text] [Related]  

  • 11. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.
    Murayama A; Marshall DC
    Gynecol Oncol; 2024 Feb; 181():83-90. PubMed ID: 38147713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost sharing for oral lenvatinib among commercially insured patients.
    Liang MI; Chen L; Aviki EM; Wright JD
    Am J Manag Care; 2024 Mar; 30(3):114-117. PubMed ID: 38457819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
    Smith AJB; O'Brien C; Haggerty A; Ko EM; Rendle KA
    Gynecol Oncol; 2024 Jul; 186():170-175. PubMed ID: 38691987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Charity Financial Assistance for Novel Oral Anticancer Agents.
    Olszewski AJ; Zullo AR; Nering CR; Huynh JP
    J Oncol Pract; 2018 Apr; 14(4):e221-e228. PubMed ID: 29443649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
    Lee C; Grigorian M; Nolan R; Binder G; Rice G
    J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.
    Seetasith A; Wong W; Tse J; Burudpakdee C
    J Med Econ; 2019 May; 22(5):414-420. PubMed ID: 30729850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
    Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
    J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.